Acerus Pharmaceuticals (ASP) Stock Price, News & Analysis

Company Overview

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; and Noctiva, a vasopressin analog indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Tefina, a clinical stage product for women with female sexual dysfunction; and Noctiva combination products, which are in the pre-clinical development stage for the treatment of benign prostatic hypertrophy, overactive bladder, and pediatric nocturnal enuresis. In addition, the company provides TriVair technology platform for pulmonary and nasal dosing. It sells its products through its salesforce in the United States and Canada; and through a network of distributors internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1,250 shs
• Average Volume: 4,719 shs
• Market Capitalization: C$2.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:ASP
• CIK: N/A
• Web: www.aceruspharma.com
• Phone: 416-679-0771
• Fax: N/A
• Employees: 14
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($4.41)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$28.08 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -54.10%

Debt

• Debt-to-Equity Ratio: 261.01
• Current Ratio: 0.67
• Quick Ratio: 0.26

Sales & Book Value

• Annual Sales: C$3.04 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 3.29
• Book Value: C($1.80) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 7,710,000
• Free Float: N/A
• Market Cap: C$2.78 million
• Optionable: Not Optionable
• Beta: 1.03